How COVID-19 is changing the production of cell therapies
Implementation of contingency plans allows for continued progress in therapy development
Subscribe
Get updates from the Cell Lines Blog delivered to your inbox.
Managing donor collections during the COVID-19 pandemic
Why a diverse apheresis center network is critical to business continuity
Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?
Why reliance on a small subset of donors could introduce risk for companies
Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)
Why established systems and relationships matter
HLA matching could bring more allogeneic cell therapies to market, faster
An expert opinion on HLA matching relevance for allogeneic cell therapies
Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies
By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match
Cell collection standards for cell therapies
A case study from the Standards Coordinating Body developed in partnership with Be The Match BioTherapies
How to overcome 3 common cell therapy supply chain disruptions
Design a tailored logistics plan to deliver